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Abstract
We studied myocardial tissue from 25 cardiac transplant recipients, who had end-stage congestive heart failure (CHF), and
from 21 control donor hearts. Concentrations of total carnitine (TC), free carnitine (FC), short-chain acylcarnitines, long-
chain acylcarnitines (LCAC) as well as carnitine palmitoyltransferase (CPT) activities were measured in myocardial tissue
homogenates and referred to the concentration of non-collagen protein. Compared to controls, the concentrations of TC and
FC as well as total CPT activities were significantly lower in patients. LCAC levels and the LCAC to FC ratio values were
significantly greater in patients than in controls. While the malonyl-CoA sensitive fraction of CPT, which represents CPT I
activity, was similar in patients and controls, the residual CPT activity after inhibition by malonyl-CoA, representing CPT II
activity, was significantly reduced in patients compared to controls. Moreover, the activity of CPT in the presence of Triton
X-100, which also represents the activity of CPT II, was significantly lower in patients than in controls. Malonyl-CoA
concentrations required for half-maximal inhibition of CPT activity were significantly greater in patients than in controls.
There was a linear relationship between ejection fraction (EF) values and concentrations of TC, FC, or total CPT activities.
Values for LCAC and the LCAC to FC ratio were inversely related to EF values. We conclude that failing heart shows
decreased total CPT and CPT II activities and carnitine deficiency that may be related to ventricle function. ß 2000
Elsevier Science B.V. All rights reserved.
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1. Introduction
Carnitine is synthesized chie£y by the liver, and to
a lesser degree, by the kidney from the amino acid
precursors lysine and methionine [1]. In plasma as
well as in the other tissues, total carnitine (TC) con-
sists of three main fractions: free carnitine (FC),
short-chain acylcarnitines (SCAC), and long-chain
acylcarnitines (LCAC). Myocardial carnitine levels
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greatly exceed plasma levels as the heart can extract
carnitine against a sixty-fold concentration gradient.
Myocardial uptake of carnitine occurs slowly by
means of a speci¢c sodium-dependent carnitine
transporter [2,3]. The mammalian heart primarily
meets its requirements for energy through the oxida-
tion of long-chain fatty acids (LCFA), where carni-
tine plays a key role as a carrier [4]. An important
step in the oxidation of fatty acids is the transloca-
tion of long-chain acyl-CoA into the inner mitochon-
drial space. This is achieved by a carnitine-mediated
translocation involving carnitine palmitoyltransferase
(CPT) I, carnitine acylcarnitine translocase and CPT
II [5]. While CPT I exists as two distinct isoforms
each with unique physiologic and kinetic properties,
CPT II is a widespread protein [6,7]. The liver con-
tains predominantly the L-isoform which has a lower
Km of about 30 mM. This Km corresponds to the
relatively low carnitine content found in the liver
[6,7]. In skeletal muscle, the main form is M-CPT
showing a Km as high as 500 mM, which corresponds
to its greater carnitine content [6,7]. The heart con-
tains both L- and M-CPT isoenzymes, and has an
intermediate Km, but the tissue levels of carnitine are
even higher than those found in skeletal muscle [6,7].
These greater levels of carnitine in heart may be re-
quired for other functions such as the regulation of
carbohydrate metabolism [7]. This e¡ect, which is
carried out by stimulation of the pyruvate dehydro-
genase complex [8], appears to account for partly the
bene¢cial e¡ects of L-carnitine in treating certain car-
diac diseases [8,9]. Other important functions of
L-carnitine in heart have been extensively reviewed
[7,10^12].
Previous studies, both in humans and in animals,
have shown that decreased levels of carnitine in my-
ocardium are associated with heart failure [7,10^13].
In this work, we measured the concentrations of car-
nitine fractions and the activities of CPT I and CPT
II in myocardial cells from patients with end-stage
congestive cardiac failure (CHF) in order to evaluate
whether the carnitine-related mechanisms of trans-
port of LCFA across the mitochondrion are altered
in failing heart. Two earlier reports have dealt with
carnitine metabolism in myocardial tissue from CHF
patients. While the study by Regitz et al. focused
solely on carnitine levels [13], the report by Maurer
and Zierz [14] only analyzed CPT activities. Our
study ¢rst documents both carnitine levels and CPT
activities in heart tissue from CHF patients
2. Material and methods
2.1. Patients
Myocardial biopsy specimens were obtained from
25 cardiac transplant recipients (20 men and ¢ve
women, aged 52.5 þ 6.1 years, mean þ S.D.): ¢ve
had idiopathic dilated cardiomyopathy (DC), 18
had coronary artery disease (CAD), and the remain-
ing two rheumatic heart disease. Hemodynamic data
are shown in Table 1.
Twelve patients had New York Heart Association
(NYHA) class IV congestive heart failure, and 13
had class III. The average left ventricular ejection
fraction (EF), as measured by radionuclide ventricu-
lography, was 20.5 þ 9.5. All patients with DC were
shown to have normal coronary arteries or minimal
atherosclerosis by coronary angiography or patho-
logic examination. Global ventricular dilatation was
seen in all cases with DC. There was no evidence of
systemic hypertension or concomitant cardiac valvu-
lar lesions. Patients with heart muscle diseases caused
by known infective agents, metabolic alterations, sen-
sitivity or toxic reactions, or speci¢c heart muscle
diseases associated with systemic or storage diseases
were not included in the study; neither were patients
with hypertrophic or restrictive cardiomyopathy. All
Table 1
Clinical and hemodynamic data
Age (years) 52.5 þ 6.1
Sex 20 male, 5 female
Functional class (NYHA) 13 (III), 12 (IV)
Etiology 18 CAD, 5 DC, 2
RHD
Mean evolution time heart failure
(months)
55.1 þ 44.2
EF (%) 20.5 þ 9.5
PCP (mmHg) 18.9 þ 9.8
MPAP (mmHg) 28.2 þ 12.1
PVR (Wood Units) 2.4 þ 1.0
Values are mean þ S.D. EF, left ventricular ejection fraction;
PCP, mean pulmonary capillary pressure; MPAP, mean pulmo-
nary artery pressure; PVR, pulmonary vascular resistance;
CAD, coronary artery disease; DC, dilated cardiomyopathy;
RHD, rheumatic heart disease.
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subjects with CAD had severe multivessel disease
documented by cardiac catheterization.
All patients, irrespective of the cause of the dis-
ease, had CHF and were considered candidates to
heart transplantation.
Left ventricular myocardial samples of both trans-
plant recipients (after cross-clamping of the aorta
before beginning cardiectomy) and control donor
hearts (n = 21; 16 men and ¢ve women, aged
32 þ 16 years) were taken, immediately frozen in liq-
uid nitrogen, and stored for subsequent biochemical
studies.
Since the amount of sample available from both
controls and patients was variable, especially in con-
trols in whom the quantity of tissue obtained was
low, it was not possible to measure CPT activity
and carnitine content in each myocardial sample.
Carnitine content alone was determined in 10 con-
trols and six patients, both carnitine concentrations
and CPT activities in 13 patients, and CPT activities
alone in 11 controls and six patients.
2.2. CPT activities and carnitine concentrations
Concentrations of TC, FC, SCAC and LCAC
were measured in myocardial tissue homogenates as
described [13], and referred to the concentration of
noncollagen protein (NCP) [15]. For determining
CPT activities [14,16], frozen myocardial biopsies
were homogenized with 19 vol of a solution contain-
ing 50 mM Tris bu¡er (pH 7.6), 100 mM KCl, 5 mM
MgSO4, and 1 mM EDTA using a hand-driven all-
glass homogenizer. Homogenates were used in a ¢nal
dilution of 1:60 (w/v). The e⁄ciency of homogeniza-
tion to disrupt the mitochondria was assessed by
determining the latency of citrate synthase activity,
a marker enzyme of the mitochondrial matrix. The
addition of the detergent Triton X-100 (0.5%, v/v) to
the homogenate led to an increase in citrate synthase
activity of 6 10% compared to the enzyme activity
without the addition of Triton X-100. This indicated
that the mitochondria were nearly completely dis-
rupted during the homogenization. In the disrupted
organelles, both CPT I and CPT II, associated with
the outer and inner mitochondrial membranes re-
spectively, would have access to substrate in the en-
zyme assays [14]. CPT activity was measured using
the isotope forward assay in the direction of palmi-
toylcarnitine formation [16], and referred to the con-
centration of NCP. The reaction mixture contained
100 mM Tris bu¡er (pH 7.6), 2 mM KCN, 0.1%
fatty-acid-free bovine serum albumin, 1 mM dithio-
threitol, 0.08 mM palmitoyl-CoA, and 5 mM DL-car-
nitine (0.04 WCi of DL-[methyl-14C]carnitine/Wmol).
The linearity regarding time and amount of sample
was checked. In some experiments, the inhibitor of
CPT I malonyl-CoA was added directly to the assay
mixture in varying concentrations ranging from 10 to
500 WM. Activity of CPT I was progressively inhib-
ited by increasing concentrations of malonyl-CoA
reaching a plateau between 200 and 400 WM malon-
yl-CoA. According to these ¢ndings, we used 400 WM
malonyl-CoA to inhibit the malonyl-CoA sensitive
fraction of CPT. The concentration required for
half-maximal inhibition (IC50) of CPT activity was
determined by double-reciprocal plots of the malon-
yl-CoA concentration versus the percent inhibition of
CPT activity as described [16]. In some experiments,
Triton X-100 was added to homogenates to give a
¢nal concentration of 0.5% (v/v), the homogenate
was kept on ice for 15 min and CPT was then mea-
sured [16]. The malonyl-CoA-sensitive fraction
would represent the activity of CPT I, while the re-
sidual fraction or the Triton X-100-treated activity
would indicate the activity of CPT II. To evaluate
the statistical signi¢cance unpaired t-test and regres-
sion analysis were used.
3. Results
Levels of TC, FC, SCAC, LCAC, and activities of
CPT I and II in patients with CHF and in controls
are shown in Table 2.
Compared to controls, the concentrations of TC
and FC were signi¢cantly lower in patients
(P6 0.001), but SCAC levels remained similar. Con-
versely, LCAC levels and the LCAC to FC ratio
values were signi¢cantly greater in patients than in
controls (P6 0.001). The activities of total CPT were
signi¢cantly lower in patients than in controls
(P6 0.05). While the malonyl-CoA sensitive fraction
of CPT, which represents CPT I activity, was similar
in patients and controls, the residual CPT activity
after inhibition by malonyl-CoA, representing CPT
II activity, was signi¢cantly reduced in patients com-
BBADIS 61975 23-10-00
M.A. Mart|¤n et al. / Biochimica et Biophysica Acta 1502 (2000) 330^336332
pared to controls. Moreover, we measured the activ-
ity of CPT in the presence of Triton X-100, which
represents the activity of CPT II, in four controls
and in six patients. These residual activities were
also signi¢cantly lower in patients than in controls.
Malonyl-CoA concentrations required for half-max-
imal inhibition of CPT activity (IC50) were signi¢-
cantly greater (P6 0.05) in patients (6.7 þ 2.1;
n = 6) than in controls (4.1 þ 1.0; n = 4).
There was a lineal relationship between EF values
and concentrations of TC (r2 = 0.614, P6 0.001;
y = 3.4x32.7), FC, or CPT activities (Fig. 1). Values
for LCAC (r2 = 0.234, P6 0.05; y =316.2x+30.5)
and the LCAC to FC ratio were inversely related
to EF values (Fig. 1). Moreover, FC concentrations
signi¢cantly correlated to total CPT activities
(r2 = 0.632, P6 0.01; y = 0.77x30.33), whereas this
correlation was inverse when we plotted such activ-
ities against the values for the ratio of LCAC to FC
(r2 = 0.525, P6 0.01; y =33.0x+39). No correlation
was found among the rest of clinical and hemody-
namic data and carnitine concentrations or CPT ac-
tivities.
4. Discussion
In homogenates of frozen tissue containing dis-
Fig. 1. Correlation between left ventricular ejection fraction
(EF) and myocardial content of free carnitine (FC), long-chain
acylcarnitines (LCAC) to FC ratio, and total carnitine palmi-
toyltransferase (CPT) activity. Linear regression equation, deter-
mination coe⁄cient and P values are shown.
Table 2
Carnitine levels and CPT activities
Controls End-stage congestive
heart failure
TC 10.8 þ 1.8 (10) 6.5 þ 2.2a (19)
FC 10.3 þ 1.8 (10) 5.4 þ 2.2a (19)
SCAC 0.40 þ 0.12 (10) 0.42 þ 0.24 (19)
LCAC 0.15 þ 0.09 (10) 0.69 þ 0.27a (19)
LCAC/FC 1.6 þ 1.1 (10) 16.5 þ 10.1a (19)
Total CPT 9.9 þ 1.5 (11) 7.6 þ 2.3b (19)
CPT I (mCoA sens) 5.8 þ 0.8 (11) 5.1 þ 1.9 (19)
CPT II (mCoA insens) 4.2 þ 0.6 (11) 2.5 þ 1.3b (19)
CPT II (Triton X-100) 5.6 þ 1.0 (4) 4.1 þ 1.3b (6)
Values indicate mean þ S.D. and subjects analyzed (in parenthe-
ses). Levels of TC, FC, SCAC and LCAC are expressed as
nmol (mg NCP)31. LCAC/FC ratio is expressed as percentage.
CPT activities are expressed as nmol min31 (mg NCP)31. TC,
total carnitine; FC, free carnitine; SCAC, short-chain acylcarni-
tines; LCAC, long-chain acylcarnitines; CPT, carnitine palmi-
toyltransferase; NCP, non-collagen protein; mCoA sens, ma-
lonyl-CoA sensitive; mCoA insens, malonyl-CoA insensitive.
aP6 0.001, signi¢cant di¡erence vs. controls.
bP6 0.05, signi¢cant di¡erence vs controls.
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rupted mitochondria, the di¡erentiation between
CPT I and CPT II is indirectly possible by means
of the inhibition of CPT I activity by malonyl-CoA
and by the in£uence of the detergent Triton X-100
on CPT activity. It is known that only CPT I but not
CPT II is inhibited by malonyl-CoA and that CPT II
is solubilized by Triton X-100 in the enzymatically
active form whereas the activity of CPT I is abol-
ished by Triton X-100 [17].
CPT I in heart has been noted to display kinetics
intermediate between those of liver and skeletal
muscle (in terms of IC50 for malonyl-CoA and Km
for carnitine) [18]. This behavior is consistent with
the ¢nding that although this tissue expresses M-
CPT I predominantly, it also contains su⁄cient L-
CPT I to account for the kinetic data[19,20]. That L-
CPT I and M-CPT I are present in the human heart
has been con¢rmed in tissue obtained during surgery
or transplant [6]. We found a 50% decrease in carni-
tine content together with normal levels of CPT I in
myocardium from patients with CHF. Given that the
heart contains high levels of carnitine and that this
tissue has a Km for carnitine around 200 WM [7], it is
not surprising that the marked reduction in carnitine
we observed does not result in any substantial varia-
tion in CPT I activity. Moreover, recent reports have
revealed that the CPT I isoform expression in heart
failure shifts from the M- to the L-isoform of CPT I
[7,21]. In support of this view, we found a rise in the
IC50 values for malonyl-CoA of CPT I in CHF pa-
tients compared with controls, which is consistent
with the possibility of a shifting ratio of M- to L-
CPT I in failing heart. Since the L-CPT I has a lower
Km for carnitine, it makes it less likely that a 50%
decrease in carnitine levels would a¡ect CPT I activ-
ity. In this regard, the group of Paulson, by using the
pivalate-induced model of secondary carnitine de¢-
ciency, documented that a heart with a 50% decrease
in carnitine content maintain normal rates of fatty
acid oxidation at a low workload, and exhibits a
moderate decrease in fatty acid oxidation at a higher
workload [22,23]. They suggested that the heart com-
pensated for the loss of L-carnitine by increasing the
expression of the L-isoform of CPT I. Since this iso-
form has a lower Km, the heart may be able to main-
tain fatty acid oxidation. Of interest, a rise in L-CPT
I has been documented in the heart of carnitine-de-
¢cient juvenile visceral steatosis mice [21]
Our results show that in failing heart there is a
reduction in total CPT activity, as well as in the
values of residual CPT activities both in the presence
of malonyl-CoA and after the addition of Triton X-
100. These data unequivocally indicate that the de-
crease in overall CPT activity in heart from patients
with CHF is mainly contributed by a fall in the ac-
tivity of CPT II. Interestingly, the ‘infantile’ form of
CPT II de¢ciency, an inherited disorder of long-
chain fatty acid oxidation, is a life-threatening dis-
ease characterized by cardiomyopathy, myopathy,
and hepatopathy, whose severity is related to a dif-
ference in levels of residual CPT II activity [24]. The
drop in CPT II activities is consistent with the
marked increase in myocardial LCAC levels, because
CPT II catalyzes the formation of long-chain acyl-
CoA from LCAC. In addition, CPT activities were
inversely correlated to values for the LCAC to FC
ratio. Our enzyme activity results contradict in part
those documented by Maurer and Zierz [14], who
found similar CPT activities in patients with CHF
and in controls with the same method we used in
the present study. It is remarkable that in the study
conducted by Maurer and Zierz the values for CPT
in CHF patients were in the same range as those
observed by us. By contrast, our CPT activities in
heart controls were substantially greater than those
documented by them. The reasons of these discrep-
ancies are unknown, but might be related to preana-
lytical variations in control samples (e.g., how sam-
ples were drawn or collected, time elapsed until
freezing, etc) or to di¡erences in the enzyme content
of the myocardial tissue analyzed.
The data presented here show that patients with
CHF have a great relative proportion of LCAC to
FC in myocardium, suggesting that FC concentra-
tions are probably insu⁄cient to cope with the met-
abolic demands of failing myocardium. Our carnitine
levels results are consistent with those by Regitz et al.
[13,25], who found a loss of myocardial carnitine and
an alteration in the TC to FC ratio in patients with
heart failure. Moreover, various animal cardiac mod-
els showed depletion of myocardial carnitine result-
ing in depression of fatty acid oxidation and cardiac
function [7,10^12,21]. We suggest that carnitine de¢-
ciency in myocardium may result from a leakage of
carnitine from the heart and a defect in myocardial
uptake via speci¢c carrier protein. In favor of this
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hypothesis, plasma carnitine concentrations have
shown to be increased in patients with heart failure
[13,25]. Also, experimental evidence for an alteration
in the carnitine carrier-mediated transport in dis-
eased myocardium is accumulating [26].
We found a signi¢cant relationship between levels
of TC, FC, or total CPT activities and EF values.
Consistently, Regitz et al. [13,25] documented a sig-
ni¢cant correlation, between myocardial FC and EF
values. Moreover, when we plotted EF values against
LCAC concentrations or the LCAC to FC ratio val-
ues, the relationship proved to be inverse. The corre-
lations observed do not necessarily mean that a de-
creased carnitine content and CPT activity is
responsible for the dysfunction observed in the fail-
ing heart. In fact, recent reports suggest that etomox-
ir, an irreversible CPT I inhibitor, actually improves
the symptoms of heart failure [27,28]. Although evi-
dence for LCAC as mediator of impaired contractile
function is still lacking, there is experimental evi-
dence for arrhythmogenicity of increased LCAC
[29]. In this regard, Bonet et al. [30] suggested that
the accumulation of LCAC may be responsible for
arrhythmias in patients with inborn errors of fatty
acid oxidation. Our results support the hypothesis
that heart carnitine system is related to ventricular
function. Yet, all data presented here must be inter-
preted with caution, because a correlation between
EF and either CPT activities or carnitine levels is
not direct proof that an alteration in the carnitine-
related supply of LCFA to mitochondria is contrib-
uting to the decrease in EF in these patients. More-
over, other subcellular organelles, in particular mi-
crosomes or peroxisomes,also contain CPT-like
enzyme activities that may contribute in some degree
to the ¢ndings of the present study [6].
Recently, we documented a marked increase in the
activities of respiratory chain enzymes in myocardi-
um from patients with heart failure [31]. Although a
decrease in both myocardial CPT activities and car-
nitine levels is apparently unrelated to an increase in
mitochondrial oxidative phosphorylation, it is tempt-
ing to hypothesize some degree of relationship be-
tween both ¢ndings. We can speculate that a reduc-
tion in the LCFA availability to myocardial cell
mitochondria might trigger an increase in the ca-
pacity of the mitochondrial respiratory chain in an
attempt to compensate for the shortage in energy. In
fact, Wang et al. [32] recently demonstrated that
CPT I is activated upon ATP depletion, suggesting
that phosphorylation may modulate the activity of
the L-CPT I isoform.
The data in this study con¢rm previous reports by
Regitz et al. [13,25] showing that myocardial carni-
tine levels are decreased in patients with heart failure
and that there is a signi¢cant correlation between
myocardial carnitine concentrations and EF in these
patients. These authors did not measure CPT activ-
ities in heart. The novel aspects documented here are
the observations that myocardial CPT activities are
decreased in heart failure patients compared to con-
trol hearts and that EF in these patients are related
to CPT activities.
Recently, two reviews drew attention to the poten-
tial therapeutical applications of carnitine and its de-
rivatives in heart disease [11,12]. They highlighted
that most published data are favorable, but clinical
trials are lacking, and that these substances are vir-
tually devoid of signi¢cant side e¡ects. Further work
will help to clarify the potential bene¢cial e¡ects of
these substances in heart failure.
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